IVUS guidance during DES implantation boosts long-term outcomes in new study

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Sarah Jane Rinehart, MD, director of cardiac imaging, Charleston Area Medical Center, Charleston West Virginia, as been using the FDA-cleared RoadMap artificial intelligence algorithm from HeartFlow in studies and in clinical used since it was cleared and said it helps cardiologists in several ways. #ACC #ACC24 #ACC2024 #Heartflow #AIhealth

Automated AI-generated measurements combined with annotated CT images can improve treatment planning and help referring physicians and patients better understand their disease, explained Sarah Jane Rinehart, MD, director of cardiac imaging with Charleston Area Medical Center.

women doctors

Five of the largest U.S. medical societies focused on cardiovascular health are one step closer to seeing their paradigm-shifting proposal become a reality.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."